Gold bug and bitcoin opponent Peter Schiff says the U.S. government’s actions in the past 78 years are partly responsible for the massive depreciation of the U.S. dollar. Using a medical bill from 1942 to illustrate the extent of the dollar’s decline, Schiff says the $70 paid to foot hospital expenses that year was equal
0 Comments
The temporary conditional exemption is still not widely used, said Michael Decker, senior vice president of policy and research at Bond Dealers of America. A bump in overall municipal issuance in October caused the number of deals using a temporary exemption that allows municipal advisors to arrange certain private placements, to increase nearly threefold, sources
0 Comments
Municipal bonds firmed by one to two basis points on Friday, only the second time this month that triple-A benchmarks moved in any direction, as lower-than-usual December supply has kept municipal rates historically low. Triple-A benchmarks have only moved three basis points in total since the beginning of the month. Investors will see a $9
0 Comments
KB Homes’ optional “Home Office Package,” available in homes throughout their footprint. Many … [+] builders are now offering such packages, and are finding strong demand. Photo Credit: Applied Photography The work-from-home trend is going to change the landscape. Literally. Homebuilders today are developing on land that would ordinarily be a “long commute,” and the
0 Comments
New York State’s looming budget gaps driven by coronavirus-related revenue losses have put it at risk for another credit downgrade. S&P Global Ratings revised the outlook on New York’s general obligation bonds to negative from stable Friday afternoon, citing near-term risks for declining tax revenues in the current 2021 fiscal year budget and in 2022.
0 Comments
UK drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest deal struck by a pharmaceutical company since the start of the Covid-19 pandemic.  The cash-and-stock takeover announced on Saturday shows the Anglo-Swedish company’s determination to strengthen its position in immunology, already a core focus, alongside cancer treatments
0 Comments